Whalesbook
Novo Nordisk is expanding its semaglutide offerings with a higher-dose Wegovy formulation to provide more treatment options for obesity patients. This comes as the company faces growing competition from generic semaglutide versions, particularly in markets like India.
Higher Dose Targets Greater Efficacy
Emil Kongshøj Larsen, Novo Nordisk's Executive Vice President (International Operations), stated that "There’s no one size that fits all obesity patients," emphasizing the need for varied treatment approaches. The 7.2 mg high-dose Wegovy is set for launch in Europe and the UK, aiming to help individuals achieve more substantial weight loss. Data shared at the European Congress on Obesity showed early responders could achieve up to 28% weight loss with this higher dose. Further data on the Wegovy pill indicated potential for up to 22% weight loss in early responders. Larsen noted that average weight loss with existing Wegovy in trials has been 17%, the highest for oral obesity medications. Clinical trial data also suggests that weight loss from the high-dose Wegovy primarily consists of fat, helping patients retain strength and mobility.
India Market Strategy
Vikrant Shrotriya, Novo Nordisk India Managing Director, confirmed plans to seek regulatory approval for the 7.2 mg dosage in India. He also highlighted the substantial opportunity within the existing dose strengths available in India, anticipating they will serve patients effectively for some time. Despite competition from domestic manufacturers offering generic semaglutide at lower prices, Larsen remains confident in Novo Nordisk's market leadership for Wegovy and Ozempic due to the expanding patient base benefiting from semaglutide. The company also presented data on semaglutide’s cardiovascular benefits, including proven risk reduction in post-menopausal women.
Long-Term Treatment Needs
Larsen described obesity as a chronic, relapsing disease, suggesting that semaglutide, like statins or insulin, likely requires sustained use for most patients to maintain results. He added that treatment plans are tailored to individual patient needs.